Trial Profile
MK0431 (Sitagliptin) Phase III Clinical Study -Pioglitazone Add-on Study for Patients With Type 2 Diabetes Mellitus.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Sitagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme; Merck Sharp & Dohme Corp.
- 12 Nov 2008 Actual end date (1 Feb 2008 to May 2008) changed, as reported by ClinicalTrials.gov.
- 23 Sep 2008 Results have been reported at EASD 2008 (44th Annual Meeting of the European Association for the Study of Diabetes).
- 11 Sep 2008 Primary endpoint `change from baseline to week 12 in proportion of glycosylated haemoglobin in the sitagliptin vs placebo groups' has been met.